Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.32 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | XBP1 | P17861 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL618046 | 0.76 | FFAR1 (0.41) | KMT2ANPC1CXCL12 | |
| SCHEMBL7310236 | 0.69 | HSD11B1 (0.44) | KMT2AMEN1NPC1MAPTCA1 | |
| SCHEMBL15346698 | 0.67 | CYP2C19 (0.40) | KMT2ACYP1A2 | |
| SCHEMBL7303726 | 0.65 | ALDH1A1 (0.44) | KMT2AMEN1MAPT | |
| SCHEMBL7307399 | 0.64 | ALDH1A1 (0.43) | KMT2AMEN1MAPT | |
| SCHEMBL9637668 | 0.64 | ALDH1A1 (0.40) | CYP1A2 | |
| SCHEMBL2921654 | 0.63 | HMGB1 (0.52) | HMGB1CXCL12MAPTCA1CA2 | |
| SCHEMBL6516217 | 0.59 | HPGD (0.62) | — | |
| SCHEMBL17285639 | 0.59 | MEN1 (0.51) | KMT2AMEN1NPC1HMGB1CXCL12 | |
| SCHEMBL8668939 | 0.59 | CA1 (0.55) | ACHEKMT2AMEN1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576094-B2 | Spiro derivatives as lipoxygenase inhibitors | ELI LILLY AND COMPANY (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1836183-A2 | SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS | Galileo Pharmaceuticals, Inc. (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006065686-A2 | SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS | GALILEO PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20060128790-A1 | Spiro derivatives as lipoxygenase inhibitors | GALILEO PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128790-A1 | Spiro derivatives as lipoxygenase inhibitors | ALOX15B, ALOX5, ALOX15 | ACHE 3505/4885KMT2A 3967/4885MEN1 4420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.